Search KRSA
Korsana Biosciences, Inc.
Nasdaq · CIK 1755237
Last close30.49
Daily change-0.71 (-2.28%)
10 Years gain-98.26%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
KRSA · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
55.0Momentum
100.0Acceleration
60.0Confidence
82.0Annual Revenue7
Quarterly Revenue22
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality16.4 / 25
Capital Efficiency7.8 / 20
Balance Sheet3.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1240.5207 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 66.3146%.
ROIC declining · MEDIUMROIC declined by 26.617 percentage points.
Key Metrics
Revenue Growth TTM252%OK
Revenue CAGR 3Y91.14%OK
Gross Margin100%OK
Operating Margin-791.12%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-96.98%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y66.31%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.07M | $2.07M | -$4.97M | -$3.31M | n/a | 100% | -239.78% | n/a | -68.55% | 3.18M |
| 2025 FY Dec 31, 2024 | $2.00M | $2.00M | -$3.63M | -$4.33M | n/a | 100% | -181.4% | n/a | -61.41% | 2.52M |
| 2024 FY Dec 31, 2023 | $0.00 | $0.00 | -$12.95M | -$21.25M | n/a | n/a | n/a | n/a | -477.32% | 2.34M |
| 2023 FY Dec 31, 2022 | $297,000.00 | $297,000.00 | -$18.54M | -$40.61M | n/a | 100% | -6,242.42% | n/a | n/a | 2.17M |
| 2022 FY Dec 31, 2021 | $3.94M | $3.94M | -$55.20M | -$36.52M | -$36.52M | 100% | -1,400.18% | -926.53% | n/a | 39.14M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $968,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-332842, 0001193125-25-277749 |
| Revenue Growth TTM | 252% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-332842, 0001193125-25-277749 |
| Revenue CAGR 3Y | 91.14% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-132193 |
| Revenue CAGR 5Y | -2.01% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-132193 |
| Gross Profit CAGR 3Y | 91.14% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-132193 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-332842, 0001193125-25-277749 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-332842, 0001193125-25-277749 |
| Operating Margin | -791.12% | Operating Income / Revenue | OK | 0001193125-26-332842, 0001193125-25-277749 |
| ROIC | -96.98% | NOPAT / Average Invested Capital | OK | 0001193125-26-332842, 0001193125-25-277749 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-332842 |
| Current Ratio | 0.82x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.23 | Revenue / Diluted Shares | OK | 0001193125-26-332842, 0001193125-25-277749 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |